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HBIG. The final study sample comprised 59 patients. The authors did not report any exclusions or refusals to participate.
Study design
The study was a case series that was conducted in a single centre. The median follow-up was 1,051 days. The authors did not report any loss to follow-up.
Analysis of effectiveness
All of the patients included in the study were accounted for in the analysis. The primary health outcome was recurrence of HBV. Recurrence of HBV was defined as the reappearance of hepatitis B surface antigen in serum after its initial disappearance following OLT.
Effectiveness results
Fifty-six patients (94.9%) survived at a median follow-up of 1,051 days.
At a median follow-up of 1,051 days after beginning treatment with IM HBIG and lamivudine, 58 patients (98.3%) did not have recurrent HBV infection, but this number included 3 patients who had died.
Clinical conclusions
The authors concluded that IM HBIG combined with lamivudine is of similar efficacy to IV HBIG combined with lamivudine in preventing the recurrence of HBV infection. 
Modelling

Outcomes assessed in the review
No details of the parameters derived from the literature were provided.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Not reported. 
Number of primary studies included
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
Measure of benefits used in the economic analysis
The measure of health benefits used was number of cases of recurrent HBV infection prevented.
Direct costs
Some resource use quantities were reported separately from the costs. The study included the direct costs to a thirdparty payer. These comprised the costs of lamivudine, IM HBIG, IV HBIG, re-transplantation, death, liver biopsy and laboratory tests. The cost data were derived from published studies and the Medicare fee schedule. Discounting was relevant as the model extrapolated the data to 5 years, but it does not appear to have been applied. The study reported the average costs. The price year was not given.
Statistical analysis of costs
Some patient level data were available, but these were treated as point estimates. The study presented median quantities with the range.
